Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.

Applied health economics and health policy2022PMID: 35441978

Authors

Stafford, Sara; Bech, Peter G; Fridhammar, Adam; Miresashvili, Nino; Nilsson, Andreas; Willis, Michael; Liu, Aiden